Literature DB >> 19759548

Downregulation of Fas gene expression in Sézary syndrome is associated with promoter hypermethylation.

Christine L Jones1, E Mary Wain, Chung-Ching Chu, Isabella Tosi, Rosalind Foster, Robert C T McKenzie, Sean J Whittaker, Tracey J Mitchell.   

Abstract

Sézary Syndrome (SS) is an aggressive leukemic variant of primary cutaneous T-cell lymphoma characterized by the presence of tumor or Sézary cells that generally display a mature memory T-cell immunophenotype. Sézary cells proliferate poorly and therefore their accumulation may be due to defective T-cell homeostasis involving resistance to apoptosis. In this study, we analyzed Fas expression in CD4+ lymphocytes at the mRNA and protein levels in a large cohort of SS patients as compared with healthy controls. Fas mRNA expression was dysregulated in 34/47 patients, with significant under- and overexpression of Fas mRNA detected in 21 and 13 patients respectively (P<0.01). Examination of cell-surface Fas expression showed correlation with the observed downregulation of mRNA in CD4+ T cells. Mutational analysis demonstrated that functional FAS gene mutations are rare. Moreover, 16 SS patients who showed significant under-expression of Fas mRNA also showed significant positional hypermethylation within the FAS CpG island, which was not present in healthy controls or SS patients determined to have normal or overexpression of Fas mRNA. These data demonstrate that dysregulation of Fas expression is a common feature of SS, and provide a rationale for targeted therapies to restore the extrinsic Fas-dependent apoptotic pathway in this malignancy.

Entities:  

Mesh:

Substances:

Year:  2009        PMID: 19759548     DOI: 10.1038/jid.2009.301

Source DB:  PubMed          Journal:  J Invest Dermatol        ISSN: 0022-202X            Impact factor:   8.551


  21 in total

1.  Structural alterations of the FAS gene in cutaneous T-cell lymphoma (CTCL).

Authors:  Jianqiang Wu; Jawed Siddiqui; Minakshi Nihal; Eric C Vonderheid; Gary S Wood
Journal:  Arch Biochem Biophys       Date:  2010-10-29       Impact factor: 4.013

Review 2.  Apoptosis and aging: increased resistance to apoptosis enhances the aging process.

Authors:  Antero Salminen; Johanna Ojala; Kai Kaarniranta
Journal:  Cell Mol Life Sci       Date:  2010-11-30       Impact factor: 9.261

Review 3.  Epigenetic biomarkers in skin cancer.

Authors:  Edward S Greenberg; Kelly K Chong; Kelly T Huynh; Ryo Tanaka; Dave S B Hoon
Journal:  Cancer Lett       Date:  2012-01-27       Impact factor: 8.679

Review 4.  Cutaneous T-cell lymphomas: a review of new discoveries and treatments.

Authors:  Tara Bloom; Timothy M Kuzel; Christiane Querfeld; Joan Guitart; Steven T Rosen
Journal:  Curr Treat Options Oncol       Date:  2012-03

Review 5.  Systemic Treatment Options for Advanced-Stage Mycosis Fungoides and Sézary Syndrome.

Authors:  Louise Photiou; Carrie van der Weyden; Christopher McCormack; H Miles Prince
Journal:  Curr Oncol Rep       Date:  2018-03-23       Impact factor: 5.075

Review 6.  Genetics and epigenetics of the skin meet deep sequence.

Authors:  Jeffrey B Cheng; Raymond J Cho
Journal:  J Invest Dermatol       Date:  2012-01-12       Impact factor: 8.551

7.  Increased Twist expression in advanced stage of mycosis fungoides and Sézary syndrome.

Authors:  Meghali Goswami; Madeleine Duvic; Alexis Dougherty; Xiao Ni
Journal:  J Cutan Pathol       Date:  2012-05       Impact factor: 1.587

Review 8.  Genome-wide epigenetics.

Authors:  Brian C Capell; Shelley L Berger
Journal:  J Invest Dermatol       Date:  2013-06       Impact factor: 8.551

Review 9.  Cutaneous T-cell lymphoma: 2016 update on diagnosis, risk-stratification, and management.

Authors:  Ryan A Wilcox
Journal:  Am J Hematol       Date:  2015-11-26       Impact factor: 10.047

Review 10.  Emerging therapies provide new opportunities to reshape the multifaceted interactions between the immune system and lymphoma cells.

Authors:  M Pizzi; M Boi; F Bertoni; G Inghirami
Journal:  Leukemia       Date:  2016-06-08       Impact factor: 11.528

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.